Precisio Biotix Doses First Patient With ClyO (LYSG101)

Precisio Biotix Therapeutics, Inc. (Precisio) Announces Dosing of a First Patient with ClyO (Staph Lysin) to Treat a Multi Drug-Resistant Prosthetic Joint Infection

DOVER, Del.--(BUSINESS WIRE)--Jul 3, 2025-

Precisio Biotix Doses First Patient With ClyO (LYSG101)

Precisio Biotix announces first dosing of ClyO (LYSG101) for multi-drug-resistant prosthetic joint infection treatment.

Real-time sequencing helps combat golden staph infections

Tracking bacterial changes during serious Staphylococcus aureus (golden staph) infection can give clinicians immediate insights to personalise treatment and improve patient outcomes.